ReviewBirth defects research2022
Toward better assessments of developmental toxicity using stem cell-based in vitro embryogenesis models.
Review in Birth defects research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Evaluation of a Novel Fluorescent Marker for Continuous Live Imaging of Preimplantation Embryos.Journal of developmental biology · 2026Article
- Human stem cell-based embryo models: innovation, ethics, and policy.Human reproduction (Oxford, England) · 2026Article
- Investigation of embryogenesis in a dish: the development and application of gastruloid models from pluripotent stem cells.Cell & bioscience · 2026Review
- Stem cell-based embryo models as a tool for reproductive biology.Molecular human reproduction · 2026Review
- Developmental and angiogenic safety profiles of novel pyridine-based chalcone.Frontiers in pharmacology · 2026Article
- Human stem cell-based embryo models: from self-organization to recapitulating development.Frontiers in cell and developmental biology · 2026Review
- Review
- Three-dimensional stem cell models of mammalian gastrulation.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Pluripotent stem cells for target organ developmental toxicity testing.Toxicological sciences : an official journal of the Society of Toxicology · 2024Review
- Validation of a mouse 3D gastruloid-based embryotoxicity assay in reference to the ICH S5(R3) guideline chemical exposure list.Reproductive toxicology (Elmsford, N.Y.) · 2024Article
- Development of Advanced Oral-on-a-Chip: Replicating the Intricate Human Oral Microenvironment.International journal of biological sciences · 2024Article
- An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.Reproductive toxicology (Elmsford, N.Y.) · 2023Article
- Developmental toxicity of remdesivir, an anti-COVID-19 drug, is implicated by in vitro assays using morphogenetic embryoid bodies of mouse and human pluripotent stem cells.Birth defects research · 2023Article
- Human-Based New Approach Methodologies in Developmental Toxicity Testing: A Step Ahead from the State of the Art with a Feto-Placental Organ-on-Chip Platform.International journal of environmental research and public health · 2022Review
- Toward better assessments of developmental toxicity using stem cell-based in vitro embryogenesis models.Birth defects research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In the past few decades, pluripotent stem cells have been explored as nonanimal alternatives to assess the developmental toxicity of chemicals. To date, numerous versions of stem cell-based assays have been reported that are allegedly effective. Nonetheless, none of the assays has become the gold standard in developmental toxicity assessment. Why? This article discusses several issues in the hope of facilitating the refinement of stem cell assays and their acceptance as the cornerstone in predictive developmental toxicology. Each stem cell assay is built on a limited representation of embryogenesis, so that multiple assays are needed to detect the diverse effects of various chemicals. To validate and compare the strengths and weaknesses of individual assays, standardized lists of reference chemicals should be established. Reference lists should consist of exposures defined by toxicokinetic data, namely maternal plasma concentrations that cause embryonic death or malformations, and also by the effects on the molecular machineries that control embryogenesis. Although not entirely replacing human or animal tests, carefully selected stem cell assays should serve as practical and ethical alternatives to proactively identify chemical exposures that disturb embryogenesis. To achieve this goal, unprecedented levels of coordination and conviction are required among research and regulatory communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.